课题基金 / 基金详情

ReTendon: development of a novel tendon repair device that accelerates healing and reduces re-rupture of tendons

ReTendon: development of a novel tendon repair device that accelerates healing and reduces re-rupture of tendons
ReTendon:开发一种新型肌腱修复装置,可加速愈合并减少肌腱再次断裂
批准号:
10038520
负责人:
金额:
$61.02万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
该项目的目的是**开发一种新型肌腱修复医疗设备,以改善肌腱损伤患者的健康状况**。肌腱损伤会使患者严重致残,通常需要手术,康复时间长,医疗费用高。需要手术修复的最常见的肌腱损伤类型是:屈肌(手):英国约18000次/年跟腱(脚):英国约62000次/年肩袖(肩):英国约9000次/年每10万人的手术数量与国外相似。多达四分之一的肌腱手术不能达到令人满意的结果,因为疤痕组织的形成不如原来的肌腱好。1 / 20到1 / 5的修复肌腱(取决于哪根肌腱断裂)会再次断裂,需要进一步的手术。re肌腱公司开发了一种新型的肌腱修复医疗设备,它可以在缝合的肌腱两端之间建立桥梁。我们的设备使肌腱更自然地重建,有可能使肌腱愈合得更快、更强,它还减少了手术后肌腱断裂的可能性,减少了再次手术的成本,减少了患者的康复时间和休息时间。我们的初步研究表明,我们的设备是安全的,并有可能改善肌腱修复。我们还建立了生产工艺,并证明了生产稳定和无菌产品的能力。这项受专利保护的工作借鉴了曼彻斯特大学在英国的突破性研究,并将由英国公司re肌腱有限公司进一步开发和商业化。这个早期项目的目的是创建完整的技术和商业数据包,使re肌腱能够获得后续投资和监管机构(MHRA)批准进行首次人体临床试验。该项目的合作伙伴是re腱有限公司(Lead, Proctor)和曼彻斯特大学(cartell),由现有团队、专家分包商和临床顾问提供支持。这个团队在生物学、工程学、工业和临床实践方面都有必要的专业知识来完成上述项目。我们预计该项目的完成将使首次人体临床试验成为可能;成功的试验将使该平台技术适用于多发性肌腱损伤、韧带损伤,并具有兽医应用的范围。该项目将为re肌腱成为软组织修复领域的全球领导者提供基础,改善患者的治疗效果,并从英国的新研究中创造商业影响。
英文摘要
The aim of this project is to **develop a novel tendon repair medical device that improves health outcomes in patients with tendon injuries**.Tendon injuries can be severely disabling to patients, often requiring an operation with long rehabilitation times and high healthcare costs.The most common types of tendon injuries that require surgical repair are:Flexor (hand): ~18,000 operations/year in UKAchilles (foot): ~ 62,000 operations/year in UKRotator cuff (shoulder): ~9,000 operations/year in UKThe number of operations per 100,000 people are similar abroad.Up to 1 in 4 tendon operations do not achieve satisfactory results due to the formation of scar tissue that works less well than the original tendon. Between 1 in 20 and 1 in 5 of repaired tendons (dependent on which tendon was broken) can break again requiring further operations.ReTendon has developed a novel tendon repair medical device, which builds a bridge between the ends of sown-together tendons. Our device enables tendons to re-build more naturally, with a potential for tendons to heal faster and more strongly, it also reduces tendons from breaking after operation, reducing reoperation costs and the length of rehabilitation and time off work for patients.Our initial research demonstrates that our device is safe and is likely to improve tendon repair. We have also established manufacturing processes and demonstrated the ability to manufacture a stable and sterile product.This patent-protected work draws on breakthrough UK research at the University of Manchester and will be further developed and commercialised by UK company ReTendon Limited.The aim of this early-stage project is to create the complete technical and commercial data package required to enable ReTendon to obtain follow-on investment and regulatory (MHRA) approval for a first clinical trial in humans.The project partners are ReTendon Ltd (Lead, Proctor) and the University of Manchester (Cartmell), supported by an existing team, expert subcontractors and clinical advisors. This team has the necessary expertise in biology, engineering, industrial and clinical practice to deliver the above project.We anticipate that completion of this project will enable a first in human clinical trial; a successful trial will then enable this platform technology to be adapted for multiple tendon injuries, ligament injuries and has scope for veterinary applications. The project will provide a basis for ReTendon to become a global leader in soft tissue repair, improving patient outcomes and creating commercial impact from novel UK research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
损伤线粒体传递机制介导成纤维细胞/II型肺泡上皮细胞对话在支气管肺发育不良肺泡发育阻滞中的作用
  • 批准号:
    82371721
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王星云
  • 依托单位:
增强子在小鼠早期胚胎细胞命运决定中的功能和调控机制研究
  • 批准号:
    82371668
  • 项目类别:
    面上项目
  • 资助金额:
    52.00万元
  • 批准年份:
    2023
  • 负责人:
    乔云波
  • 依托单位:
MAP2的m6A甲基化在七氟烷引起SST神经元树突发育异常及精细运动损伤中的作用机制研究
  • 批准号:
    82371276
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    严佳
  • 依托单位:
"胚胎/生殖细胞发育特性激活”促进“神经胶质瘤恶变”的机制及其临床价值研究
  • 批准号:
    82372327
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    马展
  • 依托单位: